Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

Also called NCT01053936

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 129 participants (enrolled count) (from the registry)
Sponsor
  • Biogen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01053936
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01053936. Randomized; no masking; primary purpose treatment. Start 2010-01-31 (actual); primary completion 2010-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
Condition
Renal Insufficiency, Chronic
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Bardoxolone methyl (amorphous dispersion)
Lead sponsor
Biogen (class: industry)

Record details

Record id
cardio:ct-nct01053936
Content hash
f432c246b7e00d293b85009c0cbba2dcdb03c72da6dc0d8b2d0ea1b1f36cacab